Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- PBYI
- Price
- 6.86
- Stock movement down
- -0.03 (-0.44%)
- Company name
- Puma Biotechnology Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 345.68M
- Ent value
- 379.75M
- Price/Sales
- 1.63
- Price/Book
- 3.00
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 9.35
- Forward P/E
- 12.47
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- 130.20%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
PBYI does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 9.35 |
| Price to OCF | 8.04 |
| Price to FCF | 8.06 |
| Price to EBITDA | 6.89 |
| EV to EBITDA | 7.57 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1.63 |
| Price to Book | 3.00 |
| EV to Sales | 1.79 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 50.39M |
| EPS (TTM) | 0.73 |
| FCF per share (TTM) | 0.84 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 212.00M |
| Gross profit (TTM) | 163.04M |
| Operating income (TTM) | 33.56M |
| Net income (TTM) | 36.98M |
| EPS (TTM) | 0.73 |
| EPS (1y forward) | 0.55 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 76.91% |
| Operating margin (TTM) | 15.83% |
| Profit margin (TTM) | 17.44% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 53.52M |
| Net receivables | 33.56M |
| Total current assets | 143.58M |
| Goodwill | 0.00 |
| Intangible assets | 43.83M |
| Property, plant and equipment | 13.04M |
| Total assets | 202.86M |
| Accounts payable | 6.39M |
| Short/Current long term debt | 41.05M |
| Total current liabilities | 82.73M |
| Total liabilities | 87.59M |
| Shareholder's equity | 115.27M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 42.99M |
| Capital expenditures (TTM) | 123.00K |
| Free cash flow (TTM) | 42.87M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 32.08% |
| Return on Assets | 18.23% |
| Return on Invested Capital | 24.42% |
| Cash Return on Invested Capital | 28.30% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 6.94 |
| Daily high | 7.21 |
| Daily low | 6.55 |
| Daily Volume | 767K |
| All-time high | 275.07 |
| 1y analyst estimate | 3.50 |
| Beta | 1.16 |
| EPS (TTM) | 0.73 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 26 Feb 2026 |
Downside potential
Loading...
Downside potential data
| PBYI | S&P500 | |
| Current price drop from All-time high | -97.51% | -0.89% |
| Highest price drop | -99.12% | -19.00% |
| Date of highest drop | 15 Nov 2024 | 8 Apr 2025 |
| Avg drop from high | -98.58% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
345.68M
Marketcap category
Small-cap
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Employees
172
Investor relations
-
SEC filings
CEO
Alan H. Auerbach
Country
USA
City
Los Angeles
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page